Risk factors associated with the development of aspiration pneumonia in patients receiving radiotherapy for head and neck cancer: retrospective study

Head & Neck ◽  
2020 ◽  
Vol 42 (9) ◽  
pp. 2571-2580
Author(s):  
Yumiko Kawashita ◽  
Shimpei Morimoto ◽  
Kensuke Tashiro ◽  
Sakiko Soutome ◽  
Masako Yoshimatsu ◽  
...  
2006 ◽  
Vol 132 (8) ◽  
pp. 874
Author(s):  
M. Schultzel ◽  
G. Robins-Sadler ◽  
K. L. Clark ◽  
M. Loscalzo ◽  
R. Weisman ◽  
...  

2015 ◽  
Vol 136 (3) ◽  
pp. 325-329 ◽  
Author(s):  
Yukinori Takenaka ◽  
Toshimichi Yasui ◽  
Keisuke Enomoto ◽  
Haruka Miyabe ◽  
Natsue Morizane ◽  
...  

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 223-223
Author(s):  
Navika Shukla ◽  
Anirudh Saraswathula ◽  
Saad A. Khan ◽  
Vasu Divi

223 Background: Despite the recent introduction of the CMS metric, OP-35, which tracks 30-day inpatient admissions and ED visits after outpatient chemotherapy administration, the risk factors driving acute care utilization (ACU) in the head and neck cancer treatment setting are not yet well understood. Further characterization of these risk factors could allow for improved care quality and reduce preventable inpatient and ED admissions. Methods: This was a retrospective cohort study utilizing the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked cancer registry-claims database. The study cohort consisted of patients aged 66 years or older diagnosed with head and neck cancer between 2004-2015 who received outpatient chemotherapy within the first two years after diagnosis. Multivariable logistic regression modeling was utilized to characterize the risk factors associated with an inpatient or ED admission within 30 days after receiving chemotherapy. Results: Of the 2,236 eligible patients, 735 (32.9%) had at least one inpatient or ED admission within 30 days of receiving outpatient chemotherapy. On multivariable analysis, cancer of the oral cavity [odds ratio (OR) 1.43; 95% confidence interval (CI) 1.04-1.96] and oropharynx/hypopharynx [OR 1.34; 95% CI 1.06-1.70] were associated with an increased odds of ACU. Other factors associated with ACU included NCI comorbidity index [OR 1.10; 95% CI 1.03-1.18], prior ACU [OR 1.06; 95% CI 1.02-1.09], second cycle of chemotherapy relative to the first cycle [OR 0.38, 95% CI 0.29-0.50], and third or greater cycle of chemotherapy [OR 0.17; 95% CI 0.13-0.21]. Certain chemotherapeutic agents also modified risk: use of an angiogenesis inhibitor [OR 0.18; 95% CI 0.06-0.45], alkylating agent [OR 1.24; 95% 1.01-1.53], plant alkaloid [OR 1.63; 95% CI 1.25-2.10], or antimetabolite [OR 2.69; 95% CI 1.78-4.09]. The most common admission diagnosis was pain (n = 243; 33.1%) followed by dehydration (n = 167; 22.7%). Conclusions: Multiple clinical variables modify risk of acute care utilization after outpatient chemotherapy in the head and neck cancer setting, providing several potential avenues of intervention for providers.


2015 ◽  
Vol 129 (7) ◽  
pp. 710-714 ◽  
Author(s):  
R Madan ◽  
A K Kairo ◽  
A Sharma ◽  
S Roy ◽  
S Singh ◽  
...  

AbstractBackground:Aspiration pneumonia is an important cause of death in head and neck cancer patients. This study therefore aimed to evaluate the risk factors associated with aspiration pneumonia in head and neck cancer patients.Methods:Hospital death records from 12 years (2000–2012) were reviewed to obtain the number of deaths. Treatment details and cause of death were analysed. Statistical analysis was performed to identify the risk factors for aspiration pneumonia.Results:The records revealed that aspiration pneumonia was the cause of death in 51 out of 85 patients. Primary tumour site (oropharynx and hypopharynx, odds ratio 3.3; 95 per cent confidence interval 1.17–9.4, p = 0.02) and advanced tumour stage (odds ratio 4.2, 95 per cent confidence interval 1.16–15.61, p = 0.02) had significant negative impacts on aspiration pneumonia related mortality.Conclusion:Advanced pharyngeal cancer patients are at an increased risk of aspiration pneumonia related death. Investigations for the early detection of this condition are recommended in these high-risk patients.


2018 ◽  
Vol 29 ◽  
pp. viii394-viii395
Author(s):  
H. Shirasu ◽  
T. Yokota ◽  
K. Fushiki ◽  
H. Inoue ◽  
M. Shibata ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document